VOY-101

Perceive Biotherapeutics, Inc. · Phase 1 active Biologic

At a glance

Generic name	VOY-101
Sponsor	Perceive Biotherapeutics, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (PHASE1, PHASE2)
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VOY-101 CI brief — competitive landscape report
VOY-101 updates RSS · CI watch RSS
Perceive Biotherapeutics, Inc. portfolio CI